Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Peter

Showing results (661-670 of 674) with videos related to

Pageof 68
Sort By:
JCO Precision Oncology|April 20, 2023
Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid CorrelatesDaniel A King, Amber R Smith, Gino Pineda, et al.
Cancer Immunology Research|October 18, 2017
A Blueprint to Advance Colorectal Cancer ImmunotherapiesDung T Le, Vanessa M Hubbard-Lucey, Michael A Morse, et al.
Genome Medicine|November 14, 2024
Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patientsXiuli Zhang, S Peter Goedegebuure, Michael Y Chen, et al.
Alcoholism, Clinical and Experimental Research|June 8, 2001
How is the liver primed or sensitized for alcoholic liver disease?H Tsukamoto, Y Takei, C J McClain, et al.
The Lancet. Oncology|June 28, 2015
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialAntoni Ribas, Igor Puzanov, Reinhard Dummer, et al.
Nature Cancer|May 12, 2026
Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trialElizabeth A R Garfinkle, Renzo Perales-Linares, Ryan C Gimple, et al.
Arxiv|December 19, 2025
ImmunoNX: a robust bioinformatics workflow to support personalized neoantigen vaccine trialsKartik Singhal, Evelyn Schmidt, Susanna Kiwala, et al.
Science (New York, N.Y.)|June 10, 2017
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeDung T Le, Jennifer N Durham, Kellie N Smith, et al.
International Journal of Cancer|July 19, 2021
Long-term exposure to air pollution and liver cancer incidence in six European cohortsRina So, Jie Chen, Amar J Mehta, et al.
Nature|October 31, 2024
Tumour evolution and microenvironment interactions in 2D and 3D spaceChia-Kuei Mo, Jingxian Liu, Siqi Chen, et al.
Pageof 68

Showing results (661-670 of 674) with videos related to

Sort By:
Pageof 68
JCO Precision Oncology|April 20, 2023
Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid CorrelatesDaniel A King, Amber R Smith, Gino Pineda, et al.
Cancer Immunology Research|October 18, 2017
A Blueprint to Advance Colorectal Cancer ImmunotherapiesDung T Le, Vanessa M Hubbard-Lucey, Michael A Morse, et al.
Genome Medicine|November 14, 2024
Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patientsXiuli Zhang, S Peter Goedegebuure, Michael Y Chen, et al.
Alcoholism, Clinical and Experimental Research|June 8, 2001
How is the liver primed or sensitized for alcoholic liver disease?H Tsukamoto, Y Takei, C J McClain, et al.
The Lancet. Oncology|June 28, 2015
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialAntoni Ribas, Igor Puzanov, Reinhard Dummer, et al.
Nature Cancer|May 12, 2026
Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trialElizabeth A R Garfinkle, Renzo Perales-Linares, Ryan C Gimple, et al.
Arxiv|December 19, 2025
ImmunoNX: a robust bioinformatics workflow to support personalized neoantigen vaccine trialsKartik Singhal, Evelyn Schmidt, Susanna Kiwala, et al.
Science (New York, N.Y.)|June 10, 2017
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeDung T Le, Jennifer N Durham, Kellie N Smith, et al.
International Journal of Cancer|July 19, 2021
Long-term exposure to air pollution and liver cancer incidence in six European cohortsRina So, Jie Chen, Amar J Mehta, et al.
Nature|October 31, 2024
Tumour evolution and microenvironment interactions in 2D and 3D spaceChia-Kuei Mo, Jingxian Liu, Siqi Chen, et al.
Pageof 68